The tetrapeptide commonly referred to as SS31 (also known as elamipretide, MTP-131, or Bendavia) has been the subject of laboratory and translational research focused on mitochondrial biology. This article provides a neutral, research-only overview of how SS31 appears in the published literature: what the compound is, the mechanistic themes investigators explore, typical experimental models, common terms encountered in papers, and limitations researchers note when interpreting the data.
What is SS31 peptide?
SS31 is a synthetic tetrapeptide designed to interact with mitochondrial membranes. In the literature it is frequently named elamipretide (and appears under research codes such as MTP-131). Structural descriptions in primary sources identify aromatic and cationic residues that favor membrane association and mitochondrial targeting in experimental systems.
How SS31 appears in the research literature
Published studies on SS31 span in vitro biophysical work, cellular assays, multiple preclinical animal models, and several clinical program reports. Reviews and mechanistic papers summarize proposed modes of interaction between SS31 and inner mitochondrial membrane components, and clinical reports describe trial designs and outcome assessments without implying clinical recommendations.
Representative research approaches
- Biophysical experiments and molecular dynamics simulations to map peptide–lipid interactions and membrane partitioning.
- Isolated mitochondria and membrane model systems to assess effects on membrane properties and ion distribution.
- Cell-culture studies examining mitochondrial morphology and biochemical markers of mitochondrial function.
- Preclinical rodent models addressing organ-specific questions (cardiac, renal, neurologic models) with histological and molecular endpoints.
- Clinical trial reports and open-label extension summaries that describe study design, endpoints, and interpretive limits.
Major study areas and mechanistic themes
Reviewed literature clusters around a few recurring mechanistic themes. Authors commonly frame findings as proposed mechanisms under active investigation rather than established clinical effects. Key themes include:
Membrane interactions and cardiolipin binding
Several studies propose that SS31 localizes to mitochondrial inner membrane interfaces and interacts with cardiolipin or other anionic lipids. This line of work uses model membranes, lipid biochemistry, and molecular simulations to describe how peptide binding can alter surface electrostatics and lipid packing in experimental systems.
Modulation of mitochondrial biochemistry
Investigators have examined how SS31 influences parameters such as reactive oxygen species (ROS) production, electron transport chain readouts, and mitochondrial permeability transition in laboratory assays. These investigations typically report mechanistic hypotheses—such as effects on electron transport or inhibition of lipid peroxidation—derived from controlled experimental measurements.
Organ- and disease-focused preclinical studies
Preclinical literature includes cardiac, renal, and neurologic models among others. In renal research, for example, reviews compile studies addressing ischemia–reperfusion and toxin-induced injury models and summarize measured endpoints (mitochondrial morphology, oxidative markers, apoptosis-related proteins, fibrosis markers). Authors often emphasize experimental context and limitations when extrapolating across models.
Model types used in SS31 studies
Readers will encounter a range of experimental systems in SS31 literature. Common model types are:
- Artificial lipid bilayers and liposome systems for biophysical characterization.
- Isolated mitochondria preparations for biochemical assays.
- Cell lines and primary cell cultures for mechanistic cellular readouts.
- Small-animal (rodent) models for organ-level investigations and histopathology.
- Clinical trial cohorts and open-label extension reports in defined patient populations, typically with explicit discussion of sample size and interpretive constraints.
Key terms readers may encounter
Familiarity with certain technical terms helps in interpreting SS31 publications:
- Cardiolipin: an anionic phospholipid enriched in the inner mitochondrial membrane mentioned frequently in mechanistic discussions.
- Membrane partitioning: describes the extent and location of peptide association with lipid bilayers.
- Molecular dynamics simulations: computational methods used to model peptide–lipid interactions at atomistic detail.
- Reactive oxygen species (ROS): commonly measured oxidative markers in mitochondrial studies.
- Mitochondrial permeability transition: a regulated change in inner membrane permeability assessed in many mechanistic studies.
Limits of the published research
Authors of reviews and primary studies frequently note limitations that affect interpretation. These include variability across experimental models, differences in endpoints and analytical methods, small sample sizes in clinical reports, and incomplete mechanistic resolution in some contexts. Reviews emphasize the need for replication, standardized assays, and careful distinction between mechanistic hypotheses and clinical outcomes.
Why research-only language matters
Using research-only phrasing clarifies that reported findings arise from controlled experiments and that published literature often presents proposed mechanisms rather than clinically validated effects. For suppliers, scientists, and readers, this framing supports accurate communication about what the evidence does and does not establish.
Selected references
For an introduction to experimental methods and summaries of clinical program reporting, consult the sources below for full details and citations:
- Biophysical and computational insights into membrane interactions: PubMed (J Biol Chem, 2020) – https://pubmed.ncbi.nlm.nih.gov/32273339/
- Comprehensive review of structural and translational literature (Int J Mol Sci, 2025) – https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/
- Review focused on renal preclinical studies (2022) – https://pmc.ncbi.nlm.nih.gov/articles/PMC9192202/
- Clinical program reporting example (TAZPOWER, Barth syndrome) – https://pmc.ncbi.nlm.nih.gov/articles/PMC9388406/
Readers interested in original methods, experimental parameters, and data should consult the primary publications listed above.
Related Peptide Titans Resources
Research Sources
Primary references and source materials used for this research-focused overview:
- pubmed.ncbi.nlm.nih.gov/32273339
- pmc.ncbi.nlm.nih.gov/articles/PMC11816484
- pmc.ncbi.nlm.nih.gov/articles/PMC9192202
- pmc.ncbi.nlm.nih.gov/articles/PMC9388406
Frequently Asked Questions
What is SS31 peptide and how is it named in the literature?
SS31 is a synthetic tetrapeptide frequently referenced as elamipretide, MTP-131, or Bendavia in published studies. Structural descriptions and sequence information are provided in primary sources that focus on mitochondrial targeting and membrane interactions.
Which experimental models do researchers use to study SS31?
Published research uses a range of models including artificial lipid bilayers, isolated mitochondria, cultured cells, rodent models, and clinical trial cohorts. Each model provides different mechanistic or translational information and has distinct interpretive limits.
What mechanisms have been proposed for SS31 in laboratory studies?
Mechanistic themes in the literature include peptide association with mitochondrial membrane interfaces, interactions with cardiolipin, modulation of membrane electrostatics and lipid packing, and effects on mitochondrial biochemical readouts such as reactive oxygen species and electron transport parameters. These are reported as hypotheses and experimental observations in controlled settings.
Are there clinical studies of SS31 reported in the literature?
Yes. The literature includes clinical program reports and trial publications that describe study designs, endpoints, and limitations. Such reports are presented in the context of research and do not imply clinical recommendations.